Search Clinical Trials in the EU

Duration

>20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

81-100 of 140 trials

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard Medicines Partially RemoteHematologyOncologyRheumatology

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visits No Placebo Standard MedicinesHematologyOncology

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteEndocrinology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyUrology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visits No Placebo Standard Medicines Partially RemoteDiabetologyInfectious DiseasesInternal Medicine

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Partially RemoteNeurologyPediatrics

Multifocal Motor Neuropathy: DNTH103 Treatment Study

We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.

Multifocal Motor Neuropathy1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Partially RemoteNeurology

Cariprazine for Adolescents with Schizophrenia

We are studying the safety and tolerability of cariprazine in adolescents aged 13 to under 18 with schizophrenia. This trial aims to see how well the medication works and its impact on health-related outcomes.

Schizophrenia>2 yearsConfirmation phase (III)>20 visits No Placebo Standard Medicines Cost ReimbursementPediatricsPsychiatry

Peripheral T-Cell Lymphoma: Lacutamab with GemOx

We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)>20 visits No Placebo Investigational Medicines Cost ReimbursementHematologyOncology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncologyPediatrics

Crohn’s Disease and Ulcerative Colitis: Tulisokibart Study

We are studying the long-term safety and effectiveness of tulisokibart in people with Crohn’s disease or ulcerative colitis. This research aims to see how well the treatment helps manage symptoms and achieve remission.

Crohn's DiseaseUlcerative Colitis>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational MedicinesGastroenterologyInternal Medicine

Cerebrolysin for CADASIL Patients

We are studying whether Cerebrolysin is safe and effective for individuals with genetically confirmed CADASIL. This trial compares it to a placebo to understand its overall benefits.

CADASIL>2 yearsEfficacy phase (II)>20 visits Standard MedicinesNeurology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard MedicinesOncologyUrology

Pulmonary Hypertension: Mosliciguat Study

We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.

Pulmonary Hypertension6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPulmonology

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesOncologyPulmonology

Immunoglobulin A Nephropathy: Povetacicept Study

We are evaluating a new treatment for adults with Immunoglobulin A Nephropathy to see if it helps reduce protein in urine and preserve kidney function. The study also looks at its effects on slowing kidney failure and improving fatigue.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)>20 visits Investigational Medicines Cost ReimbursementNephrology

Search Clinical Trials in the European Union